RedHill Biopharma Divests Talicia to an Apotex Subsidiary for $18M Upfront Plus Milestones

RedHill Biopharma divested its 70% interest in the Talicia business to a subsidiary of Apotex Health for $18 million upfront cash, plus up to $35 million in worldwide net sales milestone payments. The company said proceeds will strengthen liquidity and fund the next stage of RedHill’s gastrointestinal commercial expansion, including scaling its GI franchise and pursuing new high-value FDA-approved opportunities.